Literature DB >> 18803105

Neurosyphilis, malaria, and the discovery of antipsychotic agents.

Frances R Frankenburg1, Ross J Baldessarini.   

Abstract

Four of the most disabling human diseases are syphilis, malaria, schizophrenia, and manic-depressive illness. The history of the development of treatments for these seemingly unrelated disorders intersects at several points. Treatment of tertiary cerebral syphilis (general paresis) by inducing fever with malaria led to a Nobel Prize. Although attempts to synthesize quinine, a plant product effective against malaria, failed, these efforts encouraged industrial organic chemists to synthesize many useful substances, including dyes, antibiotics, and antihistamines. The aniline-derived dye methylene blue was a member of a new class of polycyclic chemicals, the phenothiazines. Efforts to modify phenothiazines to find an antimalarial agent also failed but led to novel antiemetic-sedative antihistamines, including promethazine, promazine, and eventually chlorpromazine--the first effective treatment for schizophrenia and mania. Chlorpromazine has antipsychotic and antimanic properties, and it revolutionized the therapeutics of psychotic illnesses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18803105     DOI: 10.1080/10673220802432350

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  10 in total

1.  Methylene Blue in the Treatment of Neuropsychiatric Disorders.

Authors:  Martin Alda
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

2.  Concomitant infection decreases the malaria burden but escalates relapsing fever borreliosis.

Authors:  Jenny Lundqvist; Christer Larsson; Maria Nelson; Marie Andersson; Sven Bergström; Cathrine Persson
Journal:  Infect Immun       Date:  2010-02-09       Impact factor: 3.441

Review 3.  Cellular and molecular actions of Methylene Blue in the nervous system.

Authors:  Murat Oz; Dietrich E Lorke; Mohammed Hasan; George A Petroianu
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

Review 4.  A bibliometric review of drug repurposing.

Authors:  Nancy C Baker; Sean Ekins; Antony J Williams; Alexander Tropsha
Journal:  Drug Discov Today       Date:  2018-01-09       Impact factor: 7.851

5.  Julius Wagner-Jauregg and the legacy of malarial therapy for the treatment of general paresis of the insane.

Authors:  Cynthia J Tsay
Journal:  Yale J Biol Med       Date:  2013-06-13

Review 6.  Brief history of syphilis.

Authors:  M Tampa; I Sarbu; C Matei; V Benea; S R Georgescu
Journal:  J Med Life       Date:  2014-03-25

7.  A Small Molecule Impedes Insulin Fibrillation: Another New Role of Phenothiazine Derivatives.

Authors:  Meghomukta Mukherjee; Jagannath Jana; Subhrangsu Chatterjee
Journal:  ChemistryOpen       Date:  2017-12-07       Impact factor: 2.911

Review 8.  Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work.

Authors:  Rajesh Kumar; Seetha Harilal; Sheeba Varghese Gupta; Jobin Jose; Della Grace Thomas Parambi; Md Sahab Uddin; Muhammad Ajmal Shah; Bijo Mathew
Journal:  Eur J Med Chem       Date:  2019-08-08       Impact factor: 6.514

9.  The Gender Affirmative Treatment Model for Youth with Gender Dysphoria: A Medical Advance or Dangerous Medicine?

Authors:  Alison Clayton
Journal:  Arch Sex Behav       Date:  2021-11-22

Review 10.  Image-guided hepatopancreatobiliary surgery using near-infrared fluorescent light.

Authors:  Floris P R Verbeek; Joost R van der Vorst; Boudewijn E Schaafsma; Merlijn Hutteman; Bert A Bonsing; Fijs W B van Leeuwen; John V Frangioni; Cornelis J H van de Velde; Rutger-Jan Swijnenburg; Alexander L Vahrmeijer
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-11       Impact factor: 7.027

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.